Editas Medicine (EDIT) Posts Smaller Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Editas Medicine Announces Second Quarter 2020 Results and Update
August 6, 2020 4:06 PM EDTRegained full control of ocular medicines under new agreement with AbbVie
BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020
Plan to file IND for EDIT-301 for sickle cell disease by end of 2020
Strengthened balance sheet through equity offering raising $216 million in gross proceeds
Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:... More
